Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 ( C V A 21) and systemic p emb r olizumab in a dvanced melanoma patients: Interim results of the CAPRA clinical trial

W. Silk, Ann; L. Kaufman, Howard; Gabrail, Nashat; M. Mehnert, Janice; L. Bryan, Jennifer; Norrell, Jacqueline; Medina, Daniel; K. Bommareddy, Praveen; R. Shafren, Darren; Grose, Mark; Zloza, Andrew

doi:10.1158/1538-7445.am2017-ct026

Public

Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 ( C V A 21) and systemic p emb r olizumab in a dvanced melanoma patients: Interim results of the CAPRA clinical trial

Published in Cancer Research • Jul 1, 2017

Authors:

Ann W. Silk

Howard L. Kaufman

Nashat Gabrail

Abstract

Abstract Background: Coxsackievirus A21 (CVA21) is a novel bio-selected oncolytic, immunotherapeutic agent. Intratumoral (i.t.) CVA21 injection can induce selective tumor-cell infection, immune-cell infiltration, IFN-γ response gene up-regulation, increased PD-L1 expression, tumor cell lysis and sys...

Subject

Medicine

Pembrolizumab

Oncolytic virus

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!